

IFW

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 13095B
In Re Application Of: <b>Robert Harris</b>			
Serial No. 10/688,638	Filing Date October 17, 2003	Examiner Unassigned	Group Art Unit 1654
Title: <b>NEW USES FOR AMINO ACID ANTICONVULSANTS</b>			
<p>Address to: <b>Commissioner for Patents</b> <b>P.O. Box 1450</b> <b>Alexandria, VA 22313-1450</b></p> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p><b>OR</b></p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>			

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
**13095B**

In Re Application: **Robert Harris**

Serial No.

10/688,638

Filing Date

October 17, 2003

Examiner

Unassigned

Group Art Unit

1654


**NEW USES FOR AMINO ACID ANTICONVULSANTS**

**Payment of Fee**



(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-3886/RCT** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.


**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:	
_____ (Date)	
_____ Signature	
_____ Typed or Printed Name of Person Signing Certificate	

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on 7/6/04 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22312-1450.	
	
_____ Signature of Person Mailing Correspondence	
_____ Typed or Printed Name of Person Mailing Certificate	


\*This certificate may only be used if paying by deposit account.

  
Signature

Dated: July 6, 2004

Mark J. Cohen  
Registration No. 32,211  
Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, NY 11530  
(516) 742-4343  
MJC:lf

cc:



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Robert Harris

**Examiner:** Unassigned

**Serial No.:** 10/688,638

**Art Unit:** 1654

**Filed:** October 17, 2003

**Docket:** 13095B

**For:** NEW USES FOR AMINO ACID  
ANTICONVULSANTS

**Dated:** July 6, 2004

**Confirmation No.:** 2598

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. United States Patent No. 5,773,475, issued June 30, 1998;
2. United States Patent No. 5,654,301, issued August 5, 1997;
3. Parsons, et al., "Modulation of NMDA receptors by glycine – introduction to some basic aspects and recent developments", Amino Acids, 14: 207-216 (1998);

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 6, 2004.

Dated: July 6, 2004

  
Mark J. Cohen

5. Wlaz, et al., "Anticonvulsant effects of eliprodil alone or combined with the glycine<sub>B</sub> receptor antagonist L-701,324 or the competitive NMDA antagonist CGP 40116 in the amygdala kindling model in rats", Neuropharmacology, 38: 243-251 (1999); and
6. Ebert, et al., "Anticonvulsant effects by combined treatment with a glycine<sub>B</sub> receptor antagonist and a polyamine site antagonist in amygdala-kindled rats", European Journal of Pharmacology, 322: 179-184 (1997).

The references were cited in a Search Report dated May 12, 2004 received from the European Patent Office. In accordance with the waiver of 37 C.F.R. § 1.98 (a)(2)(i) in effect as of June 30, 2003, applicants are not required to submit copies of the above-cited U.S. Patent references 1-2.

It is noted that the Search Report lists additional citations:

United States Patent No. 5,378,729, issued January 3, 1995;

International Publication No. WO 99/43309, published September 2, 1999;

Kohn, et al., "Synthesis and Anticonvulsant Activities of  $\alpha$ -Heterocyclic  $\alpha$ -Acetamido-N-benzylacetamide Derivatives", J. Med. Chem., 36: 3350-3360 (1993);

Andurkar, et al., "The Anticonvulsant Activities of N-Benzyl 3-Methoxypropionamides", Bioorganic & Medicinal Chemistry, 7: 2381-2389 (1999);

Toniolo, et al., "A crystal-state, solution and theoretical study of the preferred conformation of linear C <sup>$\alpha$</sup> ,  $\alpha$ -diphenylglycine derivatives and dipeptides with potential anticonvulsant activity", Int. J. Peptide Protein Res., 44: 85-95 (1994);


Billich, et al., "HIV proteinase inhibitors containing 2-aminobenzylstatine as a novel scissile bond replacement: biochemical and pharmacological characterization", Antiviral Research, 25: 215-233 (1994);

However, these six items were previously submitted in an Information Disclosure Statement dated October 17, 2003; thus, it is deemed not necessary to make these of record again and/or resubmit copies of same to the United States Patent and Trademark Office.

Applicant is submitting copies of the above-cited references 1-5, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Mark J. Cohen

Registration No. 32,211

Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

MJC:lf

**LIST OF PRIOR ART  
CITED BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.  
13095BSerial No.  
10/688,638Applicant  
Robert H. HarrisFiling Date  
October 17, 2003Group Art Unit  
1654**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA	5,773,475	6/30/98	Kohn			
	AB	5,654,301	8/5/97	Kohn, et al.			
	AC	5,378,729	1/3/95	Kohn, et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 99/43309	9/2/1999	PCT				

**OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

		Kohn H. et al., "Synthesis and anticonvulsant activities of $\alpha$ -heterocyclic $\alpha$ -acetamido-N-benzylacetamide derivatives", <i>Journal of Medicinal Chemistry, United States 29 October 1993, vol. 36, no. 22, pp. 3350-3360</i>
		Andurkar, et al., "The Anticonvulsant Activities of N-Benzyl 3-Methoxypropionamides", <i>Bioorganic &amp; Medicinal Chemistry 7 (1999), pp. 2381-2389</i>
		Toniolo, et al., "A crystal-state, solution and theoretical study of the preferred conformation of linear C. $\alpha,\alpha$ -diphenylglycine derivatives and dipeptides with potential anticonvulsant activity", <i>Int. J. Pept. Protein Res. 44. 1994, 85-95, XP001074241, , Page 85, column 1, paragraph 2, Page 86, column 1; example XIV</i>
		Billich, et al., "HIV proteinase inhibitors containing 2-aminobenzylstatine as a novel scissile bond replacement: biochemical. and pharmacological characterization", <i>Antiviral Research 25 (1994) pp. 215-233</i>
		Parsons, et al., "Modulation of NMDA receptors by glycine - introduction to some basic aspects and recent developments", <i>Amino Acids</i> , 14: 207-216 (1998)
		Wlaz, et al., "Anticonvulsant effects of eliprodil alone or combined with the glycine <sub>B</sub> receptor antagonist L-701,324 or the competitive NMDA antagonist CGP 40116 in the amygdala kindling model in rats", <i>Neuropharmacology</i> , 38: 243-251 (1999)
		Ebert, et al., "Anticonvulsant effects by combined treatment with a glycine <sub>B</sub> receptor antagonist and a polyamine site antagonist in amygdala-kindled rats", <i>European Journal of Pharmacology</i> , 322: 179-184 (1997)

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.